Alcohol and the Liver: Dose-Dependent Effects from Benefit to Cirrhosis

The liver-alcohol relationship is biphasic: low doses may confer modest cardiometabolic benefits, while chronic excess causes progressive, potentially fatal injury.

Potential Benefits (Low-Moderate Intake)

• ↑ HDL cholesterol
• ↓ Fibrinogen, ↑ fibrinolysis → reduced thrombosis
• ↑ Insulin sensitivity
• Modest BP reduction (acute)
• Caveat: Benefits vanish with >1 drink/day (women) or >2 (men); no net mortality benefit per recent Mendelian randomization studies.

Progressive Alcohol-Related Liver Disease (ARLD)

1. Steatosis (Fatty Liver): >90% of heavy drinkers; reversible with abstinence.
2. Alcoholic Steatohepatitis (ASH): Inflammation, ballooning, Mallory-Denk bodies; may progress.
3. Fibrosis → Cirrhosis: Stellate cell activation → collagen deposition → architectural distortion, portal hypertension, synthetic failure. Irreversible.

Risk Thresholds

• Men: >21 standard drinks/week; Women: >14 drinks/week → significant fibrosis risk.
• Binge pattern (>5 drinks/occasion) especially harmful.
• Synergy with obesity, HCV, HBV, genetic variants (PNPLA3, TM6SF2).

Clinical Guidance

• Screen with AUDIT-C; assess liver stiffness (FibroScan) if risk factors.
• Abstinence is only proven therapy for ASH/cirrhosis.
• No "safe" threshold for those with existing liver disease.

Moderation is not protective for the liver — the dose-response is linear for harm.